Myricx Bio brings to Novartis antibody drug conjugates with a novel cancer-killing payload called an NMT inhibitor. Novartis says Myricx’s drugs could have advantages over currently available ADCs as well as those still in clinical development.
The post A $1B Acquisition Gives Novartis a Way to Stand Out in Crowded Area of Cancer appeared first on MedCity News.
